...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners >Ibrutinib in the management of Waldenstrom macroglobulinemia
【24h】

Ibrutinib in the management of Waldenstrom macroglobulinemia

机译：Ibrutinib在Waldenstrom Macroglobulinemia的管理中

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Bruton tyrosine kinase plays a critical role in hastening cell proliferation. Bruton tyrosine kinase inhibitors are a class of immunotheraputic agents that disrupt this signaling pathway. Ibrutinib, a novel Bruton tyrosine kinase inhibitor approved by the Food and Drug Administration (FDA) for the treatment of Waldenstrom macroglobulinemia in patients who have failed treatment with other agents, has emerged as an important therapeutic agent in the management of Waldenstrom macroglobulinemia and other plasma cell dyscrasias. Ibrutinib has shown to increase progression free survival and improve overall mortality. We present a review of ibrutinib, beginning with an overview of the Bruton tyrosine kinase pathway and clinically relevant gene mutations impacting treatment and prognosis for patients with Waldenstrom macroglobulinemia, followed by evidence supporting therapeutic indications for ibrutinib, and detailing its safety and efficacy evidence, current clinical guidelines, adverse effects and their management, and finally challenges of drug resistance. We also present findings on newly developed Bruton tyrosine kinase inhibitors in the therapeutic pipeline to provide readers insight into this rapidly evolving corner of oncology pharmacy practice.
机译：Bruton Tyrosine激酶在加速细胞增殖中发挥着关键作用。 Bruton Tyrosine激酶抑制剂是一类破坏该信号通路的免疫调味剂。 Ibrutinib，由食品和药物管理局（FDA）批准的新的Bruton酪氨酸激酶抑制剂（FDA）用于治疗与其他药物未发生治疗的患者的沃尔德莫氏癌胰岛素血症，其作为沃尔德斯莫德罗癌血症和其他血浆管理中的重要治疗剂细胞功能筛。 Ibrutinib已显示出现自由生存和改善整体死亡率。我们介绍了伊布洛替尼毕毒素的综述，从镇静酪氨酸激酶途径和临床相关的基因突变概述，影响沃尔德莫尔莫葡萄糖血症患者的治疗和预后，随后对伊布鲁西布的治疗适应症提供了证据，并详细说明其安全性和有效证据，当前临床指南，不利影响及其管理，终于抗药性挑战。我们还在治疗管道中新开发的Bruton Tyrosine激酶抑制剂的研究结果提供了读者洞察肿瘤医学实践的这种快速发展的角落。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号